Rates of GVHD and immunosuppression use
| . | BuCy MRD . | BuFlu MRD . | BuCy MUD . | BuFlu MUD . |
|---|---|---|---|---|
| GVHD | ||||
| Cumulative incidences of acute GVHD at 1 y, % (95% CI) | ||||
| Grade II-IV | 40 (32-47) | 42 (28-56) | 54 (43-63) | 60 (44-72) |
| Grade III-IV | 12 (8-18) | 13 (5-25) | 15 (9-23) | 19 (9-32) |
| Cumulative incidences of chronic GVHD at 2 y, % (95% CI) | 6.5 (3-11) | 6.7 (2-17) | 9.7 (5-17) | 21 (11-34) |
| Immunosuppression | ||||
| Cumulative incidences of initiation by 3 y, % (95% CI) | ||||
| Corticosteroid | 46 (38-54) | 51 (36-65) | 65 (54-73) | 68 (53-80) |
| Any nonsteroidal immunosuppressant | 40 (32-48) | 40 (26-54) | 58 (47-67) | 64 (47-77) |
| CNI | 36 (28-44) | 40 (26-54) | 50 (39-59) | 51 (36-65) |
| Never required IS beyond PTCy, % | ||||
| All patients | 51 | 47 | 31 | 26 |
| Patients alive at last follow-up | 49 | 50 | 24 | 30 |
| Duration of IS in those requiring IS beyond PTCy, median (IQR), d | ||||
| Corticosteroid | 57 (40-99) | 74 (41-206) | 63 (46-133) | 147 (49-481) |
| Any nonsteroidal IS | 141 (55-218) | 151 (53-354) | 162 (64-254) | 232 (87-561) |
| Pharmacologic | 142 (77-190) | 147 (78-231) | 158 (70-281) | 149 (69-264) |
| CNI | 135 (79-175) | 147 (78-231) | 156 (67-281) | 145 (62-278) |
| Phototherapeutic | 45 (28-109) | 225 (146-262) | 113 (64-148) | 612 (281-738) |
| Probability of being alive and off IS, % | ||||
| At 1 y | 61 | 53 | 53 | 51 |
| At 3 y | 53 | 48 | 49 | 56 |
| . | BuCy MRD . | BuFlu MRD . | BuCy MUD . | BuFlu MUD . |
|---|---|---|---|---|
| GVHD | ||||
| Cumulative incidences of acute GVHD at 1 y, % (95% CI) | ||||
| Grade II-IV | 40 (32-47) | 42 (28-56) | 54 (43-63) | 60 (44-72) |
| Grade III-IV | 12 (8-18) | 13 (5-25) | 15 (9-23) | 19 (9-32) |
| Cumulative incidences of chronic GVHD at 2 y, % (95% CI) | 6.5 (3-11) | 6.7 (2-17) | 9.7 (5-17) | 21 (11-34) |
| Immunosuppression | ||||
| Cumulative incidences of initiation by 3 y, % (95% CI) | ||||
| Corticosteroid | 46 (38-54) | 51 (36-65) | 65 (54-73) | 68 (53-80) |
| Any nonsteroidal immunosuppressant | 40 (32-48) | 40 (26-54) | 58 (47-67) | 64 (47-77) |
| CNI | 36 (28-44) | 40 (26-54) | 50 (39-59) | 51 (36-65) |
| Never required IS beyond PTCy, % | ||||
| All patients | 51 | 47 | 31 | 26 |
| Patients alive at last follow-up | 49 | 50 | 24 | 30 |
| Duration of IS in those requiring IS beyond PTCy, median (IQR), d | ||||
| Corticosteroid | 57 (40-99) | 74 (41-206) | 63 (46-133) | 147 (49-481) |
| Any nonsteroidal IS | 141 (55-218) | 151 (53-354) | 162 (64-254) | 232 (87-561) |
| Pharmacologic | 142 (77-190) | 147 (78-231) | 158 (70-281) | 149 (69-264) |
| CNI | 135 (79-175) | 147 (78-231) | 156 (67-281) | 145 (62-278) |
| Phototherapeutic | 45 (28-109) | 225 (146-262) | 113 (64-148) | 612 (281-738) |
| Probability of being alive and off IS, % | ||||
| At 1 y | 61 | 53 | 53 | 51 |
| At 3 y | 53 | 48 | 49 | 56 |
Note: The percentages of patients not requiring immunosuppression were calculated using the numbers of patients within a group who did not use immunosuppression beyond PTCy as the numerators and either all patients in that group or patients in that group alive at last follow-up as the denominators. The probabilities of being alive and off immunosuppression were calculated from the multistate models (Figure 1C).
CI, confidence interval; IQR, interquartile range; IS, immunosuppression.